Medicare utilization — JORDANN OLSON
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J2356 | Injection, tezepelumab-ekko, 1 mg | 16,170 | 19 | $0 | $230,375 |
| J3380 | Injection, vedolizumab, 1 mg | 11,100 | 13 | $0 | $182,501 |
| J1306 | Injection, inclisiran, 1 mg | 5,964 | 13 | $0 | $56,179 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 820 | 11 | $0 | $17,297 |
| 96372 | Injection of drug or substance under skin or into muscle | 175 | 53 | $0 | $1,622 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·